Zepbound and Wegovy are both once-weekly injections approved for long-term weight management, and they are not the same drug. Zepbound is tirzepatide, which acts on two gut hormone receptors, GIP and GLP-1. Wegovy is semaglutide at a 2.4 mg weekly dose, and it acts on GLP-1 alone.
In the one head-to-head trial, tirzepatide produced more average weight loss than semaglutide 2.4 mg. Wegovy has the longer cardiovascular outcomes record and a broader set of approved uses across age groups. For most people the tiebreaker is not the trial result: it is what the plan covers, what hoops it makes you jump through first, and what the cash price is when you fill.
How each medicine works, in plain terms
Both drugs copy hormones your gut releases after a meal. GLP-1 receptor agonists (incretin-based medicines) slow how fast the stomach empties, blunt appetite signals in the brain, and reduce the pull of food cues. Semaglutide does this through the GLP-1 receptor. Tirzepatide adds a second target, the GIP receptor, which appears to add to the appetite and metabolic effect.
That dual action is the main reason average results differ. It is also why the two drugs feel different to some people: the second receptor changes the balance of nausea, fullness and burping that shows up in the first weeks.
Neither drug is a short course. Both are approved as long-term treatments alongside a lower calorie diet and more physical activity, and both are studied in adults with obesity or with overweight plus a weight-related condition such as high blood pressure, sleep apnea, high cholesterol or type 2 diabetes.
Which one causes more weight loss
The direct comparison is the clearest evidence available. Over 72 weeks, tirzepatide produced 20.2% average body weight reduction versus 13.7% for semaglutide 2.4 mg (New England Journal of Medicine) in adults with obesity and without diabetes. That is a real gap, not a rounding difference, but it is an average: some people on semaglutide beat the tirzepatide average, and some people on tirzepatide lose very little.
Speed is a separate question from total loss. Both drugs start at a low dose and step up over months, so early weight change mostly reflects where you are in titration rather than which molecule is stronger. Appetite usually drops within the first few weeks, while the bigger scale changes accumulate over six months to a year and a half.
If you want a rough sense of how a percentage translates to your own numbers, run it before you argue with a formulary.
Weight loss timeline
How long a target is likely to take at a realistic rate, and what the trial percentages would put you at.
Trial averages are not promises: individual response varies widely, and results depend on staying on treatment. Faster than about 2 lb a week usually costs muscle.
Why it matters: a 6 to 7 point difference in average body weight loss can still be beaten by the drug you can actually stay on for two years.
Zepbound vs Wegovy cost: what you actually pay
Four numbers drive the Zepbound vs Wegovy cost question, and only one of them is the sticker price: the pharmacy list price, whether your plan covers weight-loss drugs at all, your share once it does (a flat copay or a percentage coinsurance), and the self-pay price if you skip insurance. Both manufacturers sell single-dose vials through their own direct channels at prices well under standard pharmacy list, and telehealth providers bundle the medicine with clinician visits at their own rates.
Tracked cash prices for tirzepatide run from $99 to $399 a month, with a median of $202.
No provider matches that filter. .
See every provider we track, with filters and sorting
Semaglutide prices sit in their own band, and the spread between the cheapest and dearest option is usually wider than the gap between the two molecules.
No provider matches that filter. .
See every provider we track, with filters and sorting
Read the monthly figure as a subscription, not a purchase. Dose escalation can change the price on some plans and pricing tiers, and a year on treatment is the number that matters for a household budget.
What a year actually costs
Programmes quote a monthly headline. Add the medication, the labs and the renewal price and the real number is usually different.
Advertised prices change often and intro pricing rarely lasts. Ask what the renewal rate is before you commit to a plan.
Insurance mechanics that decide access
Coverage, not clinical preference, is the most common reason people end up on one drug rather than the other. Employer plans frequently carve out anti-obesity medicines entirely, so the drug is not merely on a high tier, it is excluded. Under longstanding federal rules, Medicare Part D plans exclude products used only for weight loss, which is why the additional approved uses matter so much for older adults.
- Prior authorization: your prescriber must document BMI, weight-related conditions and prior attempts before the plan pays.
- Step therapy: some plans require a trial of the preferred GLP-1 first, which is why plenty of people start on one brand and move to the other.
- Deductible phase: before the deductible is met you may pay close to the full negotiated price, then far less.
- Copay versus coinsurance: a flat copay is predictable; coinsurance of 20% to 30% on a high-cost drug is not.
- Quantity limits and reauthorization: renewals often require proof of a minimum percentage of weight loss to keep coverage.
Ask the plan two specific questions: is the drug on the formulary at all, and what is the documented step therapy sequence. If the answer to the first is no, compare the plan’s exclusion against self-pay rather than chasing an appeal you will lose.
Insurance or cash pay, which is cheaper
Going through insurance is not automatically cheaper. Deductibles, copays and prior authorisation can make a cash-pay programme the better deal.
Coverage is never something a programme can promise: plans decide, prior authorisation is routine for GLP-1 medicines, and denials are common. Confirm with your own plan before choosing.
Tirzepatide providers on price versus access
Lowest monthly price
Cheapest verified plan for a new self-pay patient.
- Amazon One Medical$17/mo
- LifeMD$19/mo
- PlushCare$20/mo
- Hims$22/mo
- Strut Health$25/mo
Best on accessibility
Who can actually get seen, and how fast.
- Zealthy9 / 10
- Found9 / 10
- Teladoc Health8.8 / 10
- LifeMD8.5 / 10
- Amazon One Medical8 / 10
Ranked from our own scores, recomputed as data changes. Providers cannot pay for a place.
Dose schedules and how titration differs
Both drugs start low to limit nausea. Wegovy steps through 0.25 mg, 0.5 mg, 1 mg and 1.7 mg before reaching the 2.4 mg maintenance dose, usually with four weeks at each step. Zepbound starts at 2.5 mg and moves to 5 mg after four weeks, with further increases to 7.5 mg, 10 mg, 12.5 mg and 15 mg as needed and tolerated.
That gives Zepbound more maintenance rungs. Someone who stalls can often move up a step, while Wegovy’s ceiling is the 2.4 mg dose. On the other hand, a person who tolerates semaglutide well may reach a stable dose sooner and stay there.
Semaglutide also exists in tablet form as Rybelsus, approved for type 2 diabetes rather than weight management, and oral semaglutide products for weight have been the subject of ongoing regulatory activity. If a tablet is part of the conversation, confirm the exact product and the approved use on the label your prescriber is working from, because the injectable and oral doses are not interchangeable.
Side effects: which one is harder to tolerate
The side effect profiles overlap heavily, because the mechanisms overlap. Gastrointestinal effects dominate in both, are worst in the days after a dose increase, and usually ease with time at a steady dose.
- Nausea, diarrhea, vomiting and constipation
- Abdominal pain, indigestion and burping, reported more with tirzepatide
- Injection site reactions, fatigue and headache
- Reduced appetite that can tip into skipped meals and low protein intake
- Hair thinning, reported by some users of both drugs during rapid weight loss
Head-to-head tolerability was broadly similar in the direct trial, with gastrointestinal complaints common on both arms. In practice, individual response varies more than the averages: some people cannot get past the second Wegovy step and do fine on Zepbound, and the reverse happens too. Slower titration, smaller meals, less fat and enough fluid do more for symptoms than switching molecules on the first bad week.
Warnings, contraindications and monitoring
Both drugs carry a boxed warning about thyroid C-cell tumors seen in rodent studies, and both are contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Neither should be used by anyone with a known serious allergic reaction to the active ingredient.
- Pancreatitis: severe, persistent abdominal pain that may radiate to the back needs prompt medical assessment.
- Gallbladder disease: rapid weight loss raises gallstone risk; report right upper abdominal pain, fever or jaundice.
- Low blood sugar: the risk rises sharply when these drugs are combined with insulin or a sulfonylurea, so those doses often need review.
- Kidney injury: dehydration from vomiting or diarrhea can hurt kidney function, especially in people already at risk.
- Diabetic retinopathy: people with existing retinopathy need monitoring during rapid glucose improvement.
- Delayed gastric emptying: tell any anesthesia team before a procedure, and report vomiting of old food.
- Pregnancy: neither is used for weight management in pregnancy, and both should be stopped in advance of a planned pregnancy per label guidance.
- Oral contraceptives: tirzepatide can reduce the effectiveness of oral hormonal birth control around dose changes, so a backup method may be advised.
Routine monitoring is unglamorous and useful: weight, blood pressure, and for people with diabetes or prediabetes, glucose and HbA1c. Anyone losing weight fast should also watch protein intake and muscle mass rather than the scale alone. Contact a clinician for persistent vomiting, signs of dehydration, severe abdominal pain, or symptoms of low blood sugar.
Switching between Wegovy and Zepbound
People switch for four main reasons: a plan changed its preferred drug, a weight loss plateau, side effects that never settled, or supply problems at the pharmacy. Coverage is the most common trigger, and it explains most of the search traffic about conversion charts.
There is no official milligram-to-milligram conversion between semaglutide and tirzepatide. They are different molecules with different potency curves, so a 2.4 mg semaglutide dose does not translate into a set Zepbound dose. Prescribers commonly restart the new drug at or near its starting dose and titrate up, though some shorten the ramp for someone already tolerant to an incretin medicine. That decision belongs to the person writing the prescription.
Going the other way, from Zepbound to Wegovy, some people see weight creep back for a few weeks while the new dose builds. Weight regain after fully stopping either drug is well documented, because appetite regulation returns to baseline once the medicine clears. Plan the switch so you are not without treatment for weeks in between, and keep the diet and activity habits steady while the dose changes.
Zepbound vs Wegovy vs Ozempic vs Mounjaro
Four brands, two molecules. The confusion is a marketing artifact, not a clinical mystery.
Four Brands, Two Molecules
| Zepbound / Mounjaro | Wegovy / Ozempic / Rybelsus | |
|---|---|---|
| Active ingredient | Tirzepatide | Semaglutide |
| Receptors targeted | GIP + GLP-1 | GLP-1 only |
| Weight-loss brand | Zepbound | Wegovy |
| Diabetes brand | Mounjaro | Ozempic (injection), Rybelsus (tablet) |
| Avg weight loss (head-to-head) | 20.2% | 13.7% |
| Maintenance dose rungs | 6 (2.5-15 mg) | 5 (0.25-2.4 mg) |
| Brand | Active ingredient | Main approved use | Form |
|---|---|---|---|
| Zepbound | tirzepatide | Chronic weight management; moderate to severe obstructive sleep apnea in adults with obesity | Weekly injection |
| Mounjaro | tirzepatide | Type 2 diabetes | Weekly injection |
| Wegovy | semaglutide 2.4 mg | Chronic weight management; reducing cardiovascular risk in adults with established heart disease plus overweight or obesity | Weekly injection |
| Ozempic | semaglutide | Type 2 diabetes, with cardiovascular and kidney indications | Weekly injection |
| Rybelsus | semaglutide | Type 2 diabetes | Daily tablet |
So Zepbound is not the same as Ozempic: different molecule, different maker, different approved use. Zepbound and Mounjaro contain the same drug, and so do Wegovy and Ozempic, which is why insurers write policies around the indication rather than the ingredient.
Why people stop, and what that costs
Stopping is common, and cost leads the list. A plan drops the drug at renewal, a manufacturer savings program runs out, or a deductible resets in January and the monthly figure triples. Side effects are the second reason, usually early and usually during titration. Some people stop because they hit a goal weight and assume the job is done.
The third group quits over logistics: pharmacy backorders, a prior authorization that expires, or the paperwork burden of proving continued weight loss to keep coverage. None of that is a clinical failure, but the outcome is the same, because weight tends to return after treatment ends.
Quick tip: before you start, ask what happens at reauthorization and what the self-pay price would be if coverage stops.
How to choose, and what to do next
- Check whether your plan covers anti-obesity medicines at all, then ask which brand is preferred and what step therapy it requires.
- Get the two real numbers side by side: your out-of-pocket cost with insurance, and the lowest credible cash price for each molecule.
- Discuss your other conditions. Established heart disease, sleep apnea, type 2 diabetes or a history of pancreatitis can all point the decision one way.
- Ask about the titration plan, what to do on a bad week, and when a dose increase is appropriate.
- Confirm the follow-up schedule, including labs if you have diabetes or kidney concerns, and how refills are handled if supply is tight.
- Budget for a year, not a month, and decide in advance what you will do if the price moves.
If you cannot get the drug with the higher average result, the one your plan will pay for over 12 uninterrupted months is usually the better real-world choice.
Before You Fill: Questions to Ask
- Is this drug on my plan's formulary at all, or excluded entirely?
- Which brand is preferred, and what step therapy does the plan require?
- What is my out-of-pocket cost after the deductible versus the lowest cash price?
- Do my other conditions (heart disease, sleep apnea, diabetes) point to one drug?
- What proof of weight loss is required to keep coverage at reauthorization?
- What is the self-pay price if coverage drops mid-year?
- How are refills handled if pharmacy supply is tight?
Authoritative sources
- FDA approval announcement for tirzepatide in chronic weight management
- FDA approval announcement for semaglutide 2.4 mg in chronic weight management
- FDA announcement on the obstructive sleep apnea indication
- NIDDK reference on prescription medicines for overweight and obesity
This content is for general informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified clinician or pharmacist about your situation, and seek urgent care or call your local emergency number for severe or worsening symptoms.
